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Summary
The B-aggressive lymphoma-1 protein and ADP-ribosyltransferase BAL1/ARTD9 has been recently identified as a risk-related gene
product in aggressive diffuse large B-cell lymphoma (DLBCL). BAL1 is constitutively expressed in a subset of high-risk DLBCLs with
an active host inflammatory response and has been suggested to be associated with interferon-related gene expression. Here we identify
BAL1 as a novel oncogenic survival factor in DLBCL and show that constitutive overexpression of BAL1 in DLBCL tightly associates
with intrinsic interferon-gamma (IFNc) signaling and constitutive activity of signal transducer and activator of transcription (STAT)-1.
Remarkably, BAL1 stimulates the phosphorylation of both STAT1 isoforms, STAT1a and STAT1b, on Y701 and thereby promotes the
nuclear accumulation of the antagonistically acting and transcriptionally repressive isoform STAT1b. Moreover, BAL1 physically
interacts with both STAT1a and STAT1b through its macrodomains in an ADP-ribosylation-dependent manner. BAL1 directly inhibits,
together with STAT1b, the expression of tumor suppressor and interferon response factor (IRF)-1. Conversely, BAL1 enhances the
expression of the proto-oncogenes IRF2 and B-cell CLL/lymphoma (BCL)-6 in DLBCL. Our results show for the first time that BAL1
represses the anti-proliferative and pro-apoptotic IFNc–STAT1–IRF1–p53 axis and mediates proliferation, survival and chemo-
resistance in DLBCL. As a consequence constitutive IFNc–STAT1 signaling does not lead to apoptosis but rather to chemo-resistance in
DLBCL overexpressing BAL1. Our results suggest that BAL1 may induce an switch in STAT1 from a tumor suppressor to an oncogene
in high-risk DLBCL.
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Introduction
The B-aggressive lymphoma-1 protein and ADP-
ribosyltransferase BAL1/ARTD9, here referred to as BAL1, is
a nucleocytoplasmic shuttling protein that has been identified as
a potential risk-related gene product in diffuse large B-cell
lymphoma (DLBCL) (Aguiar et al., 2000; Juszczynski et al.,
2006). BAL1 belongs to the diphtheria-toxin-related ADP-
ribosyltransferase (ARTD) family (former PARP) of
intracellular mono- and poly-ADP-ribosyltransferases (Aguiar
et al., 2005; Aguiar et al., 2000; Hottiger et al., 2010). No auto-
modification or mono-ADP-ribosyltransferase activity has been
observed for BAL1 so far (Aguiar et al., 2005). BAL1 contains
two evolutionarily conserved macrodomains. Macrodomains
have been recently shown to act as a binding module for free
and protein-linked mono- or poly-ADP-ribose (Moyle and
Muir, 2010; Timinszky et al., 2009). BAL1 is constitutively
expressed in a subset of aggressive chemo-resistant high-risk
subtypes of DLBCL, which are associated with an active but
ineffective IFNc-mediated host inflammatory response (HR)
(Aguiar et al., 2000; Juszczynski et al., 2006). BAL1 has been
suggested to be involved in lymphocyte migration and
modulation of IFN-signaling-related gene expression in
DLBCL (Juszczynski et al., 2006). However, the exact
molecular functions of endogenous BAL1 and its regulatory
mechanisms in aggressive DLBCL have not been investigated
and remain to be elucidated.
DLBCL is a clinically heterogeneous lymphoid malignancy and
the most common subtype of non-Hodgkin’s lymphoma in adults,
with one of the highest mortality rates (Shaffer et al., 2012).
DLBCL has been subdivided into distinct classes (Rosenwald et al.,
2002; Shipp et al., 2002). Recently, a high-risk subclass with worse
clinical outcomes that is associated with an active but ineffective
host inflammatory response has been identified (Monti et al.,
2005), known as HR-DLBCL. HR-DLBCL is associated with
increased expression of inflammatory mediators and downstream
targets of interferon gamma (IFNc) signaling (Monti et al., 2005).
HR-DLBCL lacks most of the common cytogenetic abnormalities
and the exact mechanisms of transformation in these tumors
remain to be elucidated (Abramson and Shipp, 2005; Monti et al.,
2005). The clinical outcome of the HR-DLBCL cluster is not
improved, despite the increased inflammatory response
(Abramson and Shipp, 2005; Monti et al., 2005). Thus, it has
been suggested that either the host immune responses are inhibited
by counter-regulatory mechanisms or HR-DLBCL tumors are
resistant to chemotherapy, or a combination of both (Abramson
and Shipp, 2005; Monti et al., 2005).
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IFNc exhibits both pro- and anti-tumor properties, depending on
the context and cancer type (Dunn et al., 2006). Initially, IFNc helps
protect the host from tumor formation and development
(immunosurveillance), but subsequently IFNc can also promote the
tumors to resist the attack (immunoediting) (Dunn et al., 2006;
Juszczyn´ski et al., 2008; Lukacher, 2002). The anti-tumor activity of
IFNc is mediated through the signal transducer and activator of
transcription 1 (STAT1) and interferon response factor 1 (IRF1)
(Taniguchi et al., 2001). Many tumors lack IRF1 or have reduced
IRF1 expression levels (Green et al., 1999). Both STAT1 and the gene
product of its major target gene IRF1 have been shown to positively
modulate p53-activated apoptotic pathways (Taniguchi et al., 2001;
Townsend et al., 2004). Remarkably, recent studies provided
evidence that STAT1 can also act as a proto-oncogene product in
solid cancers (Khodarev et al., 2004). However, the exact molecular
mechanisms of how STAT1 acts as an oncogene are not yet known.
We have identified BAL1 as a novel co-repressor for the
transcriptional repression of tumor suppressor IRF1 and a co-
activator for the transcriptional activation of the proto-oncogenes
IRF2 and B-cell CLL/lymphoma 6 (BCL6). BAL1 interacts with
the IFNc receptor (IFNGR) complex and enhances tyrosine
phosphorylation of both isoforms of STAT1 on Y701 and their
subsequent nuclear translocation, thereby promoting the nuclear
accumulation of the antagonistically acting and transcriptionally
repressive isoform STAT1b. BAL1 interacts with both STAT1
isoforms through its macrodomains in an ADP-ribosylation-
dependent manner, and together with STAT1b inhibits the IRF1
promoter. BAL1 counteracts the IFNc-dependent anti-proliferative
and pro-apoptotic IFNc–STAT1–IRF1–p53 axis and as a
consequence, mediates proliferation, chemo-resistance and
survival in high-risk DLBCL.
Results
BAL1 is constitutively expressed in DLBCL and is
associated with aberrant IFNc/STAT1 signaling
Previous reports showed that BAL1 is constitutively
overexpressed in high-risk primary DLBCL with an active host
inflammatory response (Aguiar et al., 2005; Aguiar et al., 2000;
Juszczynski et al., 2006). Overexpression of BAL1 has also been
observed in the aggressive ABC-DLBCL cell lines OCI-Ly3 and
OCI-Ly10 as well as in the GCB-HR-like DLBCL cell line
SUDHL7 (Aguiar et al., 2005; Aguiar et al., 2000; Juszczynski
et al., 2006). IFNc/STAT1–IRF1 signaling has been shown to
stimulate the expression of BAL1 in vitro (Juszczynski et al.,
2006; Shi et al., 2011). IFNc signaling is mediated through
activation of the IFNc receptor and Janus kinases (JAK) 1 and 2
that lead to tyrosine phosphorylation of STAT1 on Y701,
homodimerization and translocation of STAT1 to the nucleus
where it induces the transcription of IFNc-stimulated genes such
as IRF1 (Dunn et al., 2006). In order to confirm these data and to
investigate whether constitutive expression of endogenous BAL1
is associated with constitutively active STAT1 signaling and
IRF1 expression we analyzed STAT1 activity in different BAL1-
expressing and -non-expressing DLBCL cell lines including the
chemo-resistant GCB-related HR-DLBCL cell line SUDHL7.
Indeed, our immunoblot analysis of BAL1, STAT1, pSTAT1,
STAT2, pSTAT2 and IRF1 expression, revealed that
constitutively expressed BAL1 is tightly associated with
intrinsic IFNc signaling and constitutively active STAT1
(Fig. 1A,B). Moreover, our STAT1-knockdown analysis using
siRNA revealed that constitutive expression of BAL1 is strictly
dependent on the transcriptional activity of STAT1 (Fig. 1C).
Subsequent chromatin immunoprecipitation analysis revealed
that endogenous STAT1 is recruited to the BAL1 promoter
(Fig. 1D), strongly indicating that STAT1 directly activates
BAL1 gene expression. STAT2 activity appears to be normal in
all DLBCL cell lines tested and not involved in upregulation of
BAL1 in HR-DLBCL cells, demonstrated by the absence of
phosphorylated STAT2. The observed IFNc-induced BAL1
expression tightly correlates with the induced activity of
STAT1 in the ABC-DLBCL cell lines OCI-Ly3 and OCI-Ly10.
However, the lower expression levels of BAL1 in OCI-Ly3 and
OCI-Ly10 could also be mediated through the constitutively high
activity of NF-kB family members in these ABC DLBCL cell
lines (Davis et al., 2010; Ngo et al., 2011; Shaffer Iii et al., 2012).
Surprisingly, tumor suppressor IRF1, a major target of STAT1
(Taniguchi et al., 2001), is strongly downregulated in the
presence of both constitutively and inducibly expressed BAL1,
whereas it is upregulated in the absence of constitutively
expressed BAL1 (Fig. 1B). These observations indicate that
BAL1 might act as a transcriptional repressor of the IRF1 gene.
Interestingly, our analysis of primary DLBCL tumors revealed
that 18% of the primary tumor samples analyzed showed positive
nuclear staining for all three analyzed markers IRF2, STAT1-
pY701 and STAT1-pS727, whereas benign tissue did not show
this pattern (Fig. 1E; supplementary material Fig. S1D,E).
BAL1 inhibits tumor suppressor IRF1 and activates the
proto-oncogene BCL6 to mediate proliferation
In order to test whether BAL1 inhibits the tumor-suppressing
IFNc–STAT1–IRF1 axis and thus directly stimulates cell
proliferation, we first analyzed the proliferation of SUDHL7
cells in which BAL1 had been knocked down (SUDHL7-
shBAL1) and control cells (SUDHL7-shmock). Remarkably, this
experiment revealed that knockdown of BAL1 strongly inhibits
proliferation (Fig. 2A; supplementary material Fig. S2A). We
next investigated whether BAL1 is directly required for the
transcriptional downregulation of tumor suppressor genes and
upregulation of proto-oncogenes involved in proliferation and
survival in DLBCL. We first analyzed the expression levels of
the IFNc/STAT1-dependent tumor suppressors and oncogene
products such as STAT1, IRF1 and IRF2. Our results
demonstrate that the expression of tumor suppressor IRF1 is
strongly upregulated in BAL1-knockdown cells, whereas the
expression level of the proto-oncogene IRF2 is strongly reduced
(Fig. 2B,C). In contrast, the expression of STAT1 and its
isoforms is not regulated by BAL1 in SUDHL7 (Fig. 2C;
supplementary material Fig. S2B). STAT1 exists in two mayor
isoforms, the full-length isoform STAT1a, which mainly acts as a
sequence-specific activator of gene expression and STAT1b,
lacking a complete transactivation domain and acting as a
transcriptional repressor and antagonist of STAT1a (Baran-
Marszak et al., 2004; Zakharova et al., 2003). Remarkably, our
expression analysis demonstrates that BAL1 also stimulates the
expression of another IFNc/STAT1-independent crucial proto-
oncogene BCL6, while concomitantly repressing the tumor-
suppressor PR-domain-containing 1 (Prdm1) gene, the gene
product of which is the B-lymphocyte-induced-maturation
protein-1 (BLIMP1), an antagonist of BCL6 (Fig. 2B,C). The
observed transcriptional upregulation of BCL6 by BAL1 is also
consistent with previous reports demonstrating that subsets of
high-risk DLBCL are dependent on BCL6 (Saito et al., 2009).
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BCL6 is overexpressed in the majority of patients with aggressive
DLBCL (Saito et al., 2009). Constitutive expression of BCL6
mediates lymphomagenesis through aberrant proliferation and cell
survival (Saito et al., 2009). Remarkably, BAL1 also enhances the
expression of BAL2/ARTD8 and the BAL2/ARTD8 target, the
oncogenic PIM1 kinase (Cho et al., 2009a) (Fig. 2B). BAL2/
ARTD8 is another macrodomain-containing ARTD family member
(Cho et al., 2009b; Goenka and Boothby, 2006; Goenka et al., 2007).
Next we tested whether BAL1 directly regulates BCL6 and IRF1
gene expression. Indeed chromatin immunoprecipitation analysis of
SUDHL7 cells revealed that endogenous BAL1 is recruited to both
the STAT1-dependent IRF1 promoter and to the STAT1-
independent BCL6 promoter (Fig. 2D), strongly indicating that
BAL1 directly repress IRF1 gene expression and stimulates BCL6
gene expression on the level of transcriptional activation (Fig. 2D).
Activation of BCL6 tightly correlates with H4K16-acetylation and
RNA-PolII recruitment, whereas repression of IRF1 correlates with
absence of H4K16 acetylation and RNA-PolII recruitment (Fig. 2D).
In contrast, activation of PIM1 is not directly mediated by BCL1
(supplementary material Fig. S2D). As expected, STAT1 is not
required for the recruitment of BAL1 to the BCL6 promoter.
BAL1 inhibits the IRF1-mediated cell death and activates
BCL6-mediated survival
In order to test whether the observed stimulation of BCL6
expression and repression of IRF1 by BAL1 also has direct
effects on cell survival we treated SUDHL7 BAL1-knockdown
and sh-mock control cells with etoposide and/or doxorubicin and
subsequently analyzed the survival and proliferation as well as
gene expression (Fig. 3A–C). Remarkably, these experiments
revealed that BAL1 not only blocks IFNc–STAT1–IRF1-
mediated apoptosis and inhibition of growth, but also reverses
the chemo-resistance of SUDHL7 (Fig. 3A,B). Absence of BAL1
strongly increases the expression of pro-apoptotic and anti-
proliferative gene products including p21, BAD, p53 or CASP3
while simultaneously downregulating the expression of pro-
survival gene products such BCL2 or BCL-XL (Fig. 3B). IRF1
has been shown to induce both ligand-dependent (extrinsic) and
ligand-independent (intrinsic) caspase-mediated apoptosis (Stang
et al., 2007). Recent studies demonstrated that IRF1 inhibits the
expression of pro-survival members of the BCL2 family and
induces the expression and activation of pro-apoptotic and anti-
proliferative gene products, including p53, p21 and CASP3
Fig. 1. BAL1 is constitutively expressed in
DLBCL associated with constitutively active
STAT1 signaling. (A) Immunoblot analysis of
untreated GCB-DLBCL cell lines (OCI-Ly1,
SUDHL4 and SUDHL6), ABC-DLBCL cell lines
(SUDHL2, U2932, OCI-Ly3 and OCI-Ly10) and
GCB-HR-DLBCL cell line SUDHL7. Whole-cell
extracts were separated by SDS-PAGE, blotted and
subsequently probed with antibodies for STAT1,
pSTAT1(Y701), pSTAT1(S727), STAT2,
pSTAT2(Y690), BAL1, IRF2, BCL6 and tubulin.
(B) Immunoblot analysis of STAT1 signaling in
GCB-, ABC- and HR-GCB-DLBCL cell lines
untreated or treated with 1000 U/ml IFNc for
8 hours. GCB-DLBCL cell line (SUDHL6), ABC-
DLBCL cell lines (U2932, OCI-Ly3 and OCI-Ly10)
and the GCB-HR-DLBCL cell line SUDHL7 were
untreated or treated with IFNc for 8 hours and then
whole-cell extracts separated by SDS-PAGE and
subsequently probed with antibodies for BAL1,
BAL2/ARTD8, BBAP/DTX3L STAT1,
pSTAT1(Y701), pSTAT1(S727), IRF1, BCL6 and
tubulin. (C) Immunoblot analysis of BAL1 and
STAT1 expression using whole-cell extracts of
SUDHL7-simock and siSTAT1-knockdown cells
untreated or treated with 1000 U/ml IFNc for
8 hours. (D) Chromatin immunoprecipitation (ChIP)
analysis of the BAL1 promoter for H4K16-
acetylation, STAT1, BAL1 and RNA-Pol-II
recruitment in SUDHL7 cells, using anti-STAT1,
anti-BAL1, anti RNA-Pol-II, anti-H4K16Ac and
control (Ctr) antibodies. (E) Analysis of primary
DLBCL tumors: the bars indicate the percentage of
positive nuclear staining for IRF2 alone and for all
three analyzed markers IRF2, pSTAT1(Y701) and
pSTAT1(S727) in primary DLBCL tumors and
benign samples. For a detailed description of the
scoring system see Materials and Methods and
supplementary material Tables S3, S4.
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(Choo et al., 2006; Schwartz et al., 2011; Shi et al., 2011).
Conversely, it has been previously demonstrated that BCL6 can
also suppress both the basal and the induced expression levels of
tumor-suppressor genes PRDM1/BLIMP1 and p53, the cyclin-
dependent kinase inhibitor gene p21 as well as the anti-apoptotic
proto-oncogene BCL2 in DLBCL (Phan and Dalla-Favera, 2004;
Saito et al., 2009). Interestingly, phosphorylation and inactivation
of the pro-apoptotic protein BAD is strongly reduced in absence
of BAL1 (Fig. 3B). However, phosphorylation of BAD at S112 is
probably not directly regulated by BAL1 but rather through
BAL2 and its target, the oncogenic kinase PIM1. Several studies
showed that phosphorylation of BAD on serine 112 is also
mediated by PIM1 and contributes to cell survival in B-cell
lymphoma (Aho et al., 2004; Chen et al., 2008; Yan et al., 2003).
The observed concomitant overexpression of BCL2 and BCL6
in SUDHL7 cells also indicates that BAL1 blocks BCL6-mediated
repression of the BCL2 gene, which is frequently disrupted in
DLBCL (Saito et al., 2009). We next investigated whether the
siRNA-mediated knockdown of STAT1 could inhibit the pro-
apoptotic and/or anti-proliferative pathways in absence of BAL1
and thus could rescue proliferation and/or survival in these cells.
These experiments revealed that siRNA-mediated knockdown of
STAT1 in SUDHL7 cells indeed blocks the IRF1-mediated pro-
apoptotic and anti-proliferative pathways (Fig. 3D–F). However,
Fig. 2. BAL1 inhibits IRF1 and activates BCL6 to mediate
proliferation in DLBCL. (A) Cell proliferation analysis of
SUDHL7-parental, stable SUDHL7-shmock and BAL1-
knockdown cells over 120 hours, was assessed by a Trypan
Blue exclusion assay. Cells were seeded at 0.26106 cells/ml in
triplicate in six-well dishes and counted every day for 5 days.
Values are means 6 s.d. from three independent experiments
performed in triplicate. (B) Immunoblot analysis of tumor
suppressor gene and proto-oncogene products. Parental wild-
type SUDHL7, shmock-RNA and BCL1-shRNA knockdown
cells were untreated or treated with 1000 U/ml IFNc for 8 hours
and then whole-cell extracts separated by SDS-PAGE, blotted
and subsequently probed with antibodies for BAL1, BAL2,
STAT1, IRF1, IRF2, BCL6, BLIMP1, PIM1, PIM2 and tubulin.
(C) Gene expression analysis of stable SUDHL7 shmock RNA
and BCL1-shRNA knockdown cells. mRNAs were isolated
from transient SUDHL7 shRNA knockdown cells and BAL1,
STAT1, IRF1, IRF2, IFNGR2 and BCL6 mRNA levels were
measured by qPCR and normalized against GAPDH. (D) ChIP
analysis of IRF1 and BCL6 promoters for H4K16-acetylation,
STAT1, BAL1 and RNA-Pol-II recruitment in SUDHL7 cells
using anti-STAT1, anti-BAL1, anti RNA-Pol-II, anti-H4K16Ac
and control (Ctr) antibodies.
Journal of Cell Science 126 (9)1972
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the observed proliferation defects and increased cell death in
siBAL1 cells could not be fully rescued in presence of siSTAT1
RNA, indicating first that STAT1 itself is required for survival and
proliferation, most probably through IRF2, and second, the
presence of overexpressed BCL6 is equally important for
survival in this cell line (Fig. 3D–F).
BAL1 forms complexes with STAT1a and STAT1b through
its macrodomains and is recruited by STAT1 to its
target promoters
Since tumor suppressor IRF1 is a major target of STAT1 we
investigated whether BAL1 could form a complex with STAT1
or other IFN-related STAT members in vivo. We first performed
co-immunoprecipitation experiments with HA-tagged BAL1 and
FLAG-tagged STAT1-6 transiently coexpressed in HEK293
cells, as well as with endogenously expressed BAL1 and
STAT1 in SUDHL7 cells. Our interaction studies revealed that
BAL1 specifically interacts with both STAT1 and STAT2
(Fig. 4A), indicating that endogenous BAL1 forms complexes
with both IFNc-induced STAT1 homodimers (Fig. 4B).
Moreover, BAL1 interacts with both STAT1a and STAT1b
isoforms (Fig. 4C). No interaction between BAL1 and other
STATs (STAT3–6) could be observed under the tested conditions
(Fig. 4A). We next tested which domain of BAL1 is required for
the observed interaction by performing co-immunoprecipitation
experiments with HA-tagged full-length BAL1 and deletion
mutants coexpressed together with FLAG-tagged STAT1 or
STAT2 in HEK293 cells. Remarkably, these mapping
Fig. 3. BAL1 inhibits the IRF1-mediated pro-
apoptotic pathways and activates the BCL6-
mediated survival pathways. (A) Cell
proliferation analysis of parental SUDHL7 cells,
stable SUDHL7 shmock and BAL1-knockdown
cells treated with etoposide (Etopo; 25 mM) and/or
doxorubicin (Doxo; 5 mM) was assessed by a
Trypan Blue exclusion assay. Cells were seeded at
0.26106 cells/ml in triplicate in six-well dishes,
treated as indicated and counted every day for 5
days. Values are means 6s.d. from three
independent experiments performed in triplicate.
(B) Immunoblot analysis of pro-apoptotic and
survival factors. SUDHL7 shmock-RNA and
BAL1-shRNA knockdown cells were untreated or
treated with Etoposide (25 mM) for 24 hours and
then whole-cell extracts separated by SDS-PAGE,
blotted and subsequently probed with antibodies
for BAL1, BCL2, BCL-xL, PIM1, BAD, pBAD-
S112, p53, p21, Casp3, cleaved Casp3 and tubulin.
(C) Cell viability analysis of parental SUDHL7
cells, stable SUDHL7 shmock and BAL1-
knockdown cells untreated (control, c) treated with
etoposide (E; 25 mM) and/or doxorubicin (D;
5 mM) was assessed by a Trypan Blue exclusion
assay. Cells were seeded at 0.26106 cells/ml in
triplicate in six-well dishes, treated as indicated
and counted every day for 5 days. Values are mean
percentages from three independent experiments
performed in triplicate. (D) Cell proliferation
analysis of untreated SUDHL7-si mock, siBAL1,
siSTAT1 and siSTAT1/BAL1 knockdown cells.
(E) Cell viability analysis of SUDHL7-simock,
siBAL1, siSTAT1 and siBAL1/siSTAT1-
knockdown cells untreated (control, c) or treated
with etoposide (25 mM) and doxorubicin (5 mM)
was assessed by a Trypan Blue exclusion assay.
Cells were seeded at 0.26106 cells/ml in triplicate
in six-well dishes, treated as indicated and counted
every day for 5 days. Values are means from three
independent experiments performed in triplicate.
(F) Immunoblot analysis of siSTAT1 knockdown
cells. SUDHL7 simock-RNA, STAT1-siRNA and
STAT1-siRNA/BAL1-siRNA knockdown cells
were untreated or treated with Etoposide (25 mM)
for 24 hours and then whole cell extracts separated
by SDS-PAGE, blotted and subsequently probed
with antibodies for STAT1, BAL1, IRF1, IRF2
and BCL6.
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experiments revealed that the observed interactions between
BAL1 with STAT1 are mediated through both macrodomains
(Fig. 4D; supplementary material Fig. S3A) and thus might
be dependent on n-ADP-ribosylation. Subsequent co-
immunoprecipitation experiments revealed that the interaction
is indeed mediated by (mono)-ADP-ribosylation (Fig. 4E). Thus,
our results suggest a potential regulatory connection between
ADP-ribose binding modules and mono-ADP-ribosylation-
dependent signaling and gene expression in high-risk DLBCL
and other B-cell lymphomas. STAT1 is modified in vitro by
BAL2/ARTD8 and ARTD10 (data not shown). However, we
have found no evidence so far that STATs are ADP-ribosylated in
vivo, and thus we were unable to elucidate the exact mechanisms
in vivo. Analyzing protein mono-ADP-ribosylation in vivo is a
difficult task because antibodies specifically recognizing mono-
ADP-ribosylated glutamate or arginine residues are lacking and
ADP-ribosylation of proteins in vivo is not easily analyzed
by mass spectrometry (Hottiger et al., 2010). Moreover, there
are no ARTD-family-member-specific ARTD/PARP inhibitors
available that would specifically target BAL2, BAL3 or other
Fig. 4. See next page for legend.
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mono-ADP-ribosylating ARTD family members (Hottiger et al.,
2010; Wahlberg et al., 2012). We could not observe any effects
on STAT1-dependent signaling and gene expression using
Olaparib or Veliparib, two ARTD/PARP inhibitors highly
specific to ARTD1 and ARTD2 (data not shown), also
indicating that the enzymatic activity of ARTD1 and/or
ARTD2 is not required for these BAL1/ARTD9-dependent
processes.
Recent studies showed that overexpression of STAT1b, the
antagonistic isoform of STAT1a increases the growth rate of
cells and their resistance to drug-induced apoptosis and cell cycle
arrest by repressing STAT1a target genes such as p21 and IRF1
in human B cells (Baran-Marszak et al., 2004). We therefore
performed IRF1-promoter-driven luciferase reporter assays with
BAL1, STAT1a and STAT1b, in the BAL1-negative DLBCL cell
line U2932 (Fig. 4F). Indeed, coexpression of BAL1 wild-type or
macrodomain deletion mutants together with STAT1a or
STAT1b, respectively, along with an IRF1-promoter-driven
luciferase reporter in U2932 cells showed that overexpression
of BAL1 wild-type together with STAT1b synergistically
downregulated the IRF1-promoter-driven luciferase reporter
upon IFNc stimulation, even in presence of STAT1a, whereas
no BAL1-mediated repression was observed with BAL1-
macrodomain deletion mutants, suggesting that the observed
inhibitory effect is directly mediated through the macrodomain-
dependent interaction of BAL1 with STAT1b (Fig. 4F). Next we
tested whether STAT1 is required for the recruitment of BAL1 to
its STAT1-dependent target promoters. Indeed chromatin
immunoprecipitation analysis in A549 cells ectopically
expressing HA-tagged BAL1 independent of STAT1
(supplementary material Fig. S3B,C) revealed that the
recruitment of BAL1 to the IRF1 promoter is strictly dependent
on STAT1 (Fig. 4G,H).
BAL1 stimulates the phosphorylation and nuclear
translocation of STAT1
We next investigated whether BAL1 could modulate the balance
between transcriptionally active STAT1a and transcriptionally
repressive STAT1b complexes in the nucleus through stimulation
of STAT1a and STAT1b phosphorylation on tyrosine 701. Indeed,
our phosphorylation analysis revealed that BAL1 stimulates the
phosphorylation of both STAT1a and STAT1b on Y701 but not on
serine 727 of the transcriptionally activating isoform STAT1a
(Fig. 5A). IFNGR–JAK2-mediated phosphorylation of STAT1 on
Y701 is required for STAT1 dimerization and its nuclear
translocation (Darnell et al., 1994; Mowen and David, 2000).
Phosphorylation on Y701 also enhances the nuclear shuttling by
triggering the nuclear retention of the shuttling STAT1a and
STAT1b, which are kept in the nucleus until tyrosine
dephosphorylation occurs (Meyer et al., 2003). JAK2 is thought
to phosphorylate STAT1 on Y701 in the cytoplasm, whereas JAK1
seems to be required for phosphorylation on Y701 in the nucleus,
preventing nuclear export of STAT1 (Meyer et al., 2003; Mowen
and David, 2000). However, phosphorylation on S727 in the
transactivation domain of STAT1a can also occur independently
of STAT1 tyrosine phosphorylation (Decker and Kovarik, 2000).
BAL1 might, therefore, mainly influence the shuttling kinetics
of STAT1. Our subsequent subcellular fractionation analysis
confirmed that BAL1 is indeed required for the constitutive
exclusively nuclear localization of STAT1 in HR-DLBCL
(Fig. 5B). Finally, our co-immunoprecipitation analysis
revealed that BAL1 interacts with the IFNGR1 complex but
not with the pY701-specific tyrosine phosphatase PTBN1 in HR-
DLBCL (Fig. 5C), indicating that BAL1 may directly stimulate
JAK2-mediated phosphorylation of STAT1 and thereby promote
the nuclear accumulation of the antagonistically acting and
transcriptionally repressive isoform STAT1b. Remarkably, a
recent study provided the first evidence that the BAL1-related
BAL2/ARTD8 promotes the survival of myeloma cells by
inhibiting the kinase activity of c-Jun N-terminal kinase 1
(JNK1) (Barbarulo et al., 2012). Since phosphorylation of
STAT1a on S727 is not affected by BAL1, our results indicate
that BAL1 influences the nuclear activities of the
transcriptionally repressive isoform STAT1b thereby tipping
Fig. 4. BAL1 forms an ADP-ribosylation-dependent complex with STAT1
and represses the IRF1 promoter together with STAT1b. (A) Co-
immunoprecipitation of BAL1 and STATs overexpressed in HEK293 cells.
HEK293 cells were co-transfected with expression vectors for HA-tagged
BAL1 full length along with FLAG-tagged STAT1, STAT2, STAT3, STAT4,
STAT5 or STAT6 and subsequently stimulated for 1 hour with 1000 U/ml
IFNc. HA–BAL1 and STAT1 complexes were then co-immunoprecipitated,
separated on SDS-PAGE, blotted and subsequently probed with antibodies for
HA (BAL1) and FLAG tag (STATs). (B) Interaction of endogenous BAL1 and
STAT1 is partially dependent of IFNc. SUDHL7 cells were stimulated for
1 hour with 1000 U/ml IFNc and endogenous BAL1 and STAT1 complexes
subsequently co-immunoprecipitated using an anti-BAL1 antibody. Complexes
were then separated on SDS-PAGE, blotted and probed with antibodies against
endogenous BAL1 and STAT1. (C) BAL1 interacts with both isoforms of
STAT1. HEK293 cells were co-transfected with expression vectors for HA-
tagged BAL1 full length along with FLAG-tagged STAT1a or STAT1b and
subsequently stimulated for 1 hour with 1000 U/ml IFNc. HA–BAL1 and
STAT1 complexes were then co-immunoprecipitated, separated on SDS-
PAGE, blotted and probed with antibodies for HA (BAL1) and FLAG tag
(STATs). (D) Mapping of the interaction domains in BAL1. HEK293 cells were
co-transfected with expression vectors for HA-tagged BAL1 full length, or
deletion mutants [deletion of macro domain 1 and 2 (Dm1 and Dm2) or
catalytic domain (DCD)] along with FLAG-tagged STAT1, and subsequently
stimulated for 1 hour with 1000 U/ml IFNc. HA–BAL1 and STAT1 complexes
were then co-immunoprecipitated, separated on SDS-PAGE, blotted and
probed with antibodies for HA (BAL1) and FLAG tag (STAT1). (E) Co-
immunoprecipitation of endogenous BAL1 and STAT1 in the presence of
ADP-ribose. SUDHL7 cells were stimulated for 1 hour with 1000 U/ml IFNc
and endogenous BAL1 and STAT1 complexes were subsequently co-
immunoprecipitated in the presence of increasing concentrations of ADP-ribose
(0.01–1 mM) using an anti-BAL1 antibody. BAL1-STAT1 complexes were
then separated on SDS PAGE, blotted and subsequently probed with antibodies
against endogenous BAL1 and STAT1. (F) BAL1 inhibits the IRF1-promoter-
driven luciferase in U2932 cells. BAL1-negative U2932 cells were seeded in
12-well dishes at 0.46106 cells/ml and co-transfected with an IRF1-promoter-
driven luciferase reporter vector (500 ng DNA/ml) along with expression
vectors for BAL1 wild type, 3x-NLS-BAL1 wild type or BAL1-macrodomain
deletion mutants (BAL1Dm1 or BAL1Dm2), STAT1a (first and middle left
panels) or STAT1b (middle left, middle right and right panels; 800 ngDNA/ml)
and with the control reporter plasmid, pRL-hTK (100 ng/ml; TK-Renilla–
luciferase control, Promega). The cells were then treated with 1000 U/ml IFNc
for 10 hours or left untreated. IRF1-promoter-Luciferase activities are
normalized to the luciferase activities of the internal TK-Renilla–luciferase
control and presented as means from 5 independent experiments performed in
triplicate 6 standard deviations. (G) ChIP analysis of IRF1 promoter for
H4K16-acetylation, STAT1, HA–BAL1 and RNA-Pol-II recruitment in si-
mock- and siSTAT1-RNA-treated A549 knockdown cells ectopically
expressing HA-tagged BAL1 using anti-STAT1, anti-HA, anti RNA-Pol-II,
anti-H4K16Ac and control (Ctr) antibodies. (H) IRF1 gene expression analysis
in A549 control cells and A549 cells ectopically expressing HA-tagged BAL1.
IRF1 mRNA levels were measured by qPCR and normalized against GAPDH.
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the antagonistic balance between STAT1 dimers activating
transcription and STAT1 dimers repressing transcription.
Discussion
In this study, we identified BAL1/ARTD9 acting as a novel IFNc-
specific oncogenic survival factor in high-risk DLBCL. We further
showed that constitutive overexpression of BAL1 in DLBCL
tightly associates with intrinsic IFNc signaling and constitutive
nuclear activity of STAT1. BAL1 counteracts the IFNc-dependent
anti-proliferative and pro-apoptotic IFNc–STAT1–IRF1–p53 axis
while concomitantly activating IFNc/STAT1-dependent (i.e.
IRF2-mediated) and IFNc/STAT1-independent (i.e. BCL6/
BCL2-mediated) anti-apoptotic-pro-survival pathways. As a
consequence, overexpression of BAL1 in HR-DLBCL mediates
cell proliferation chemo-resistance and survival in high-risk
DLBCL. The observed inhibition of tumor suppressor IRF1 and
simultaneous upregulation of the proto-oncogenes IRF2, BCL2 and
BCL6 by BAL1 strongly correlates with the phenotype of high risk
DLBCL in vitro and the clinical outcome of HR-DLBCL
(Abramson and Shipp, 2005; Monti et al., 2005).
IRF1 mediates anti-proliferative and pro-apoptotic effects in
cancer cells in a context-dependent and cell-type-specific manner
(Choo et al., 2006). In the absence of antagonistic regulatory
factors, increased expression and activation of IRF1 inhibits the
expression of pro-survival members of the BCL2 family and
simultaneously induces the expression and activation of pro-
apoptotic and anti-proliferative gene products, including p53, p21
and CASP3 (Choo et al., 2006; Schwartz et al., 2011; Shi et al.,
2011). IRF2, an antagonist of IRF1 is known to act as an
oncogene product in various types of cancer and when
overexpressed in cancer, IRF2 can abolish the tumor
suppression function of IRF1 (Choo et al., 2006). Although loss
of IRF1 alone is not associated with spontaneous tumor
development in mice, it greatly increases tumor susceptibility
in combination with loss of other tumor suppressor proteins such
as p53 (Nozawa et al., 1999). On the other hand, it has been
previously demonstrated that BCL6 can also suppress both, the
basal and the induced expression levels of tumor suppressors p53
and the cyclin-dependent kinase inhibitor p21 (Phan and Dalla-
Favera, 2004; Saito et al., 2009). Loss or mutation of p53 are
observed in about 20% of patients with high risk DLBCL and
have statistically significant negative impact on progression-free
survival (Stefancikova et al., 2011). Loss or mutation of p53 is
associated with a shorter survival after R-CHOP treatment
(Stefancikova et al., 2011). Thus the observed BAL1-mediated
downregulation of tumor-suppressors IRF1 and simultaneous
upregulation of BCL6 represents another molecular mechanism
inactivating the p53/IRF1 pro-apoptotic pathway in high-risk
DLBCL-expressing wild-type p53.
Remarkably, our study provides the first evidence that BAL1 not
only blocks IFNc–STAT1–IRF1-mediated apoptosis and inhibition
of growth, but also reverses the chemo-resistance in high-risk
DLBCLs. Our results also strongly indicate that STAT1 acts as an
oncogene in high-risk HR-DLBCL with an active host inflammatory
response. This activity is at least partially mediated by BAL1. BAL1
facilitates the oncogenic functions of STAT1 by counteracting the
pro-apoptotic IFNc–STAT1–IRF1 axis. Moreover, together with
STAT1b, BAL1 may negatively regulate a tumor suppressor
network, thereby inducing a switch in STAT1 from a tumor
suppressor to an oncogene. This also explains why constitutive
IFNc–STAT1 signaling does not lead to apoptosis but rather to
survival and chemo-resistance in HR-DLBCL (Fig. 6). Recent
studies showed that aberrant nuclear localization and activity of
STAT1 leads to radio- and chemo-resistance in solid cancers
(Khodarev et al., 2004; Khodarev et al., 2009; Khodarev et al., 2012;
Stronach et al., 2011; Weichselbaum et al., 2008).
Strikingly, our studies also demonstrate that BAL1 interacts
with the IFNGR complex and enhances tyrosine phosphorylation
Fig. 5. BAL1 specifically stimulates the
phosphorylation of STAT1a and STAT1b on Y701.
(A) Immunoblot analysis of STAT1 signaling in
SUDHL7-shmock and -BAL1-knockdown cells. Parental
wild-type SUDHL7, shmock-RNA and BAL1-shRNA
knockdown cells were untreated or treated with 1000 U/
ml IFNc for 8 hours and then whole-cell extracts were
separated by SDS-PAGE, blotted and probed with
antibodies for BAL1, STAT1, pSTAT1(Y701),
pSTAT1(S727), JAK1, pJAK1, JAK2, pJAK2, PTPN1,
PTPN2 and tubulin. (B) Subcellular fractionation
analysis of STAT1 signaling in SUDHL7-shmock and
BAL1-shRNA knockdown cells. The cells were
untreated or treated with 1000 U/ml IFNc for 8 hours
and then nuclear and cytoplasmic cell extracts were
separated by SDS-PAGE, blotted and probed with
antibodies for BAL1, STAT1, pSTAT1(Y701),
pSTAT1(S727), ARTD1(PARP1) and tubulin. (C) Co-
immunoprecipitation analysis of endogenous BAL1-
tyrosine-kinase/-phosphatase complexes in SUDHL7
cells. Endogenous BAL1/IFNGR complexes were co-
immunoprecipitated using an anti-BAL1 antibody.
Complexes were then separated by SDS-PAGE, blotted
and probed with antibodies against endogenous BAL1,
IFNcR1, pJAK1, pJAK2 and PTPN1.
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of both STAT1 isoforms, STAT1a and STAT1b, on Y701, and
their subsequent nuclear translocation, thereby promoting the
nuclear accumulation of the antagonistically acting and
transcriptionally repressive isoform STAT1b. Thus, BAL1
influences the nuclear activities of the transcriptionally
repressive isoform STAT1b, tipping the antagonistic balance
between STAT1 dimers activating transcription and STAT1
dimers repressing transcription. However, the exact molecular
mechanism(s) underlying the isoform- and promoter-specific
regulation of STAT1 by BAL1 remain to be elucidated in future
studies. Unfortunately, the specific antagonistic nuclear activities
of STAT1a and STAT1b, and their distinct phosphorylated and
unphosphorylated forms in particular, are in general not very well
investigated yet.
In contrast, BCL6 is not likely to be a direct target gene of
STAT1, so the observed BAL1-mediated stimulation of BCL6
expression might be caused by another unknown mechanism.
BCL6 overexpression is mediated through multiple mechanisms
in DLBCL: translocation, hypermutation of its promoter, or
inactivation of FBXO11, which results in increased levels and
stability of BCL6 (Duan et al., 2012). Transcriptional
upregulation of BCL6 by BAL1, therefore, represents an
additional molecular mechanism for overexpression of BCL6 in
DLBCL. Moreover, the observed concomitant overexpression of
BCL2 and BCL6 in SUDHL-7 cells also indicates that BAL1
could block BCL6-mediated repression of the BCL2 gene, which
is frequently disrupted in DLBCL (Saito et al., 2007; Saito et al.,
2009). However, the exact STAT1-independent molecular
mechanisms involved in BAL1 stimulation of the
transcriptional activation of BCL6 and BCL2 have to be
thoroughly investigated in future.
Finally our study provides the first evidence for an IFNc-
dependent STAT1–BAL1–BCL6-mediated anti-apoptotic-, pro-
survival-regulatory circuit in HR-DLBCL and explains why
STAT1 could function as an oncogene in a subset of HR-
DLBCL. In addition, our observations could also provide a
molecular mechanism for the risk-related activity of BAL1 in
HR-DLBCL subsets without constitutive active STAT1
signaling. BAL1 could be directly involved in editing or
inhibiting the IFNc-dependent host immune response against
HR-DLBCL through the termination of IFNc-mediated gene
expression and inhibition of the extrinsic IFNc-induced
Fig. 6. Model for the BAL1-mediated oncogenic switch in STAT1 in HR-DLBCL. (A) Constitutively active IFNcR-JAK1/2-STAT1 signaling in HR-DLBCL
causes overexpression of BAL1, which in turn further stimulates the phosphorylation of STAT1 on Y701 and subsequently the enhanced expression of STAT1a-
dependent proto-oncogenes (i.e. BBAP/BAL1, BAL2, IRF2). Conversely, BAL1 together with STAT1b represses the transcriptional activation of tumor suppressor
IRF1. In addition, overexpression of BAL1 also enhances the expression of STAT1-independent proto-oncogenes (i.e. BCL6). (B) Overexpression of BAL1
prevents intrinsic and extrinsic IFNc-STAT1-IRF1/p53-mediated cell death pathways while simultaneously enhancing the STAT1-dependent IRF2-mediated
proliferation and STAT1-independent BCL6–BCL2-mediated survival pathways. As a consequence BAL1 induces an switch in STAT1 from a tumor suppressor
to an oncogene and mediates proliferation, survival and chemo-resistance in HR-DLBCL. (C) Inactivation of BAL1 in HR-DLBCL associated with constitutively
active STAT1 signaling reactivates the anti-proliferative and pro-apoptotic IFNc-STAT1-IRF1/p53 axis and reverses chemo-resistance in
HR-DLBCL.
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anti-proliferative and pro-apoptotic STAT1–IRF1–p53 axis.
The observed macrodomain and ADP-ribosylation-mediated
interaction between BAL1 and STAT1 as well as the BAL1-
mediated upregulation of BAL2/ARTD8 also indicates a regulatory
cross talk between BAL1 and other active members of the ARTD
family such as BAL2/ARTD8 or ARTD10 in these processes.
BAL2/ARTD8 is a macrodomain-containing ARTD family member
and an active mono-ADP-ribosyltransferase mediating survival in c-
Myc-driven Burkitt lymphoma-like tumor cells in vivo (Cho et al.,
2009a). BAL2/ARTD8 has been suggested to function as a STAT6-
specific co-regulator of IL-4-mediated gene expression and has been
suggested to be involved in mediating IL-4-induced proliferation
and protection of B-cells against apoptosis following irradiation or
growth factor withdrawal (Cho et al., 2009b; Goenka and Boothby,
2006; Goenka et al., 2007).
Together, our studies further strengthen the hypothesis that
BAL1 may serve as a novel potential drug target for treatment of
high-risk chemo-resistant diffuse large B-cell lymphoma. The
combination of classic therapeutic drugs with novel drugs
targeting STAT1 or the macrodomains of BAL1/ARTD9 might
be a strategy to increase the sensitivity of HR-DLBCL towards
classic therapy, and thus pave the way to develop novel
therapeutic strategies for the remainder of DLBCL patients
suffering from aggressive chemo-resistant high-risk host
response variants of DLBCL.
Material and Methods
Cell culture, transfections, luciferase reporter assays and generation of
stable cell lines
The human lung carcinoma cell line A549, 293HEK and DLBCL cell lines were
cultured as described previously (Hassa et al., 2005; Saito et al., 2009). The
DLBCL cell lines SUDHL2, SUDHL4, SUDHL6, SUDHL7, U2932, OCI-Ly1,
OCI-Ly3 and OCI-Ly10 were provided by Dr Riccardo Dalla-Favera (Columbia
University, NY, USA), Dr Jose Martinez-Climent (Spanish National Cancer
Research Centre, Madrid, Spain) and Dr Louis Staudt (National Institutes of
Health, Bethesda, MD, USA). 293HEK were purchased from ATCC.
Transfections of cells with plasmid DNA (for reporter assays and generation of
stable cell lines) were performed with Fugene HD, Extreme gene 9 and HP
transfection reagents (Roche Applied Science) according to the manufacturer’s
protocols. Stable cell lines were generated using a Piggyback transposon and a
BIC-miR155-precurser-RNA based shRNA-expressing system. Piggyback-
transposed cells were selected with puromycin (500 ng/ml). Transfections of
siRNA oligos (40 pmol siRNA/transfection) were performed with Lipofectamine
RNAimax reagent (Invitrogen) or Extreme gene siRNA (Roche Applied Science)
according to manufacturers’ protocols. Luciferase reporter assays were performed
as previously described (Hassa et al., 2005) and according to manufacturer’s
protocols (Promega) using the Dual Luciferase assay kit (Promega) and a TECAN
infinite M200 luminometer (Tecan Systems).
Plasmids
Human BAL1/ARTD9 cDNA was amplified by PCR from a B-cell lymphoma
cDNA library and cloned into the corresponding expression vectors (pcDNA-HA-,
pPiggyBac-EF1aprom-HA-BAL1) using NheI–NotI or NotI, respectively. BAL1-
domain deletion and GST-fusion constructs were generated by PCR and cloned into
the NheI–NotI or EcoRI–NotI sites of pcDNA-HA- and pETM-GST-MCS1,
respectively. All constructs and full-length cDNA sequences were verified by
sequencing. All empty basic Piggyback transposon vectors and expression vectors
for the latest version of Piggyback transposases were either purchased from System
Biosciences (SBI) Inc. (Mountain View, CA, USA) or provided by Dr Allan Bradley
(Wellcome Trust Sanger Institute, UK). The BIC-mir155 vector system (Chung et al.,
2006) was provided by Dr David L. Turner (Molecular and Behavioral Neuroscience
Institute, University of Michigan, Ann Arbor, USA). The siRNA and shRNA/DNA
oligos were purchased from Qiagen. The corresponding siRNA and shRNA
sequences are listed in supplementary material Table S1. FLAG–STATs were
purchased from Addgene. hIRF1-prom-luciferase reporter vectors were a gift from
Dr R. Pine (Public Health Research Institute, Newark, NJ, USA).
Reagents
Human recombinant IFNc was purchased from PeproTech, doxorubicin and
etoposide were purchased from Sigma. Tosyl-//activated Dynabeads were
purchased from Invitrogen. ADP ribose was purchased from Sigma. High-
performance glutathione–Sepharose and Ni-Sepharose were purchased from
Amersham Biosciences.
Gene expression analysis
Real-time qPCR analysis was performed essentially as described previously
(Guetg et al., 2012). Total RNA was isolated using Trizol (Invitrogen) or Tri-
Reagent (MRC Inc.) according to manufacturers’ protocols. RNA was
subsequently reverse-transcribed using the ‘High-Capacity cDNA Reverse
Transcription kit’ (Applied Biosystems) according to manufacturer’s protocols.
Real-time qPCR was performed using the Rotor-Gene 3000 (Corbett Life
Science, now Qiagen) and SYBR Green kit (Bioline) according manufacturers’
protocols using the primers listed in supplementary material Table S2. Mean
values 6 s.e.m. were calculated and plotted as graphs with GraphPad Prism
(GraphPad Software).
Chromatin immunoprecipitation
Cells were collected and crosslinked with 1% formaldehyde as described
previously (Covic et al., 2005). Chromatin fragmentation was achieved with the
Bioruptor (Diagenode). Antibodies were incubated with crosslinked chromatin
overnight at 4 C˚ and collected with Protein-A agarose/salmon sperm DNA
(Millipore) for 3 hours. After reversal of the crosslinking and digestion with
proteinase K, DNA was extracted and measured by real-time PCR using SYBR
Green and the Rotor-Gene 3000 (Corbett Life Science/Qiagen).
Expression, purification of recombinant proteins
Recombinant HIS–GST–BAL1 fusion proteins were expressed in E. coli strains
BL21 DE3-Rosetta-II, BL21 DE3-Rosetta-II-Tuner and BL21-ArcticExpress-
Rosetta-II as described previously (Timinszky et al., 2009). All purified proteins
were analyzed using Coomassie Blue staining and confirmed by western blot
analysis using the corresponding antibodies.
Interaction assays, immunoblot analysis and immunofluorescence
microscopy
Membrane, cytoplasmic, nuclear and whole-cell extracts were prepared as
described previously (Cunningham et al., 2003; Dignam et al., 1983; Hassa et al.,
2005; Okada et al., 2008; Sen et al., 2011) with minor modifications: membrane
extraction buffer contain 50 mM HEPES (pH 7.9) 150 mM sodium chloride, 1%
Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 2.5 mM sodium
pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4 1 mM EDTA, 1 mM
EGTA and cOmplete, EDTA-free Protease Inhibitor Cocktail (Roche). For
immunoprecipitation, membrane and cytoplasmic extract fractions were re-mixed.
Co-immunoprecipitation and GST pull-down assays were performed as described
previously (Hassa et al., 2005; Owen et al., 2005; Timinszky et al., 2009), except
that the antibodies used for immunoprecipitation were covalently coupled to tosyl-
activated Dynabeads (Invitrogen) according to the manufacturer’s protocols.
Immunoprecipitation buffers contained 80 mM Tris (pH 7.05), 125 mM NaCl,
25 mM potassium acetate, 1.5 mM MgCl2, 5% glycerol, 0.5% NP-40, 0.5 mM
DTT, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 0.1 mM
Na3VO4, and cOmplete, EDTA-free Protease Inhibitor Cocktail (Roche). GST
pull-down buffers contained 80 mM Tris (pH 7.05), 1.5 mM MgCl2, 150 mM
NaCl, 50 mM potassium acetate, 0.5% NP-40, 0.5 mM DTT, 2.5 mM sodium
pyrophosphate, 1 mM b-glycerophosphate, 0.1 mM Na3VO4, 5% glycerol and
cOmplete, EDTA-free Protease Inhibitor Cocktail (Roche). Immunoblot
procedures and immunofluorescence microscopy were performed as described
previously (Guetg et al., 2012; Hassa et al., 2005) using the following primary
antibodies: monoclonal mouse anti-HA and mouse anti-FLAG antibodies (both
Sigma), polyclonal rabbit anti-BAL1 antibodies (C-terminal; Millipore),
monoclonal rabbit anti-STAT1, anti-pSTAT1(Y701), anti-pSTAT1(S727), anti-
STAT2, anti-pSTAT2(Y690), anti-IRF2, anti-BLIMP1, anti-Casp3, anti-BCL2,
anti-BAD, anti-BAD-S112, anti-PIM1, anti-PIM2, anti-PTBN1, anti-JAK1, anti-
pJAK1, anti-JAK2, anti-pJAK2, anti-IFNGR1, anti-PTBN2 and anti-BCL-XL
antibodies (RabMab, Epitomics), monoclonal rabbit anti-IRF1 (RabMab, Cell
Signaling Technology), monoclonal mouse anti-tubulin, polyclonal rabbit anti-p53
and anti-BCL6 antibodies (Santa Cruz Biotechnology). The polyclonal rabbit anti-
BAL2/ARTD8 antibody was a generous gift from Avraham Raz (Karmanos
Cancer Institute, School of Medicine, Wayne State University, Detroit, Michigan
48201, USA) (Yanagawa et al., 2007). Immunofluorescently stained cells were
analyzed by fluorescence microscopy on a Leica DMI6000B automated inverted
research microscope system (Leica Microsystem). Composite images were
generated using Adobe Photoshop software.
Flow cytometry analysis, survival and proliferation assays
FACS analysis was performed with the following PE-conjugated antibodies
(Biolegend) according to manufacturer’s protocols: PE anti-human CD119 (IFNcR
a-chain) PE anti-human CD40, PE Syrian hamster IgG isotype control and PE
mouse IgG2 isotype control antibodies. PE-positive and PE-negative cells were
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sorted using a BD FACSVantage cell sorter flow cytometer (BD Biosciences). Cell
viability and proliferation were assessed by Trypan Blue exclusion and by the
WST1 assays (Roche Diagnostics) according to manufacturers’ protocols. For the
cell viability and proliferation assays cells were seeded at 0.26106 cells/ml in six-
well dishes 8 hours prior to initiation of treatment and then incubated in the
presence of PBS, DMSO (mock-treated), etoposide (20 mM) or doxorubicin
(2 mM) for 24 hours. After 24 hours the cultures were washed with medium prior
to reseeding in fresh medium for continued culture (24, 48, 72 and 96 hours).
Relative cell viability/proliferation and cell numbers are presented as means from
three independent experiments performed in triplicate 6 standard deviations.
Analysis of tissue samples
In total, 250 formalin-fixed and paraffin-embedded tissue samples were analyzed,
which consisted of 12 tonsils with reactive lymphoid hyperplasia and 238 diffuse
large B-cell lymphomas (DLBCL). Histopathological diagnosis was rendered
according to the World Health Organization classification. Two cores of 0.1 cm
diameter were punched out of each sample of the respective donor blocks and
transferred to Tissue-Micro-Array recipient blocks, from which 3 mm thick
sections were cut and mounted on Superfrost slides (Menzel Glaser). The primary
antibodies used were anti-pSTAT1(Y701) (rabbit polyclonal, Cell Signaling
Technology, dilution 1:25 in Ventana Buffers), anti-pSTAT1(S727) (rabbit
monoclonal, Epitomics Inc., dilution 1:400 in Ventana Buffers) and anti-IRF2
(rabbit monoclonal, Epitomics Inc., dilution 1:50 in Ventana Buffers). Staining
was performed with the Ventana Discovery Ultra automated staining system
(Ventana Medical Systems Inc.), operated according to the manufacturer’s
instructions and using solely Ventana reagents during the procedure. Detection
was performed with the ChromoMap DAB detection kit using Ultra Map Anti Rb
HRP. Negative controls were performed by omission of the primary antibodies.
Slides were counterstained with Hematoxylin, dehydrated and mounted. Staining
intensity was assessed with a light microscope, allocating a semi-quantitative score
to each core. For all three markers, the approximate percentage of stained nuclei
was recorded. The scoring was undertaken as follows: ,10% was scored as 1, 10–
50% as 2, 50–80% as 3 and .80% as 4; negative staining was scored as 0. Scoring
was omitted for cores not containing appropriate tissue or in cores with artifacts
resulting from crushing (see also supplementary material Tables S3, S4).
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